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Abstract:  In this review we discuss the development of paramagnetic liposomes 
incorporating MRI contrast agents and show how these are utilized in cellular imaging   
in vitro. Bi-functional, bi-modal imaging paramagnetic liposome systems are also described. 
Next we discuss the upgrading of paramagnetic liposomes into bi-modal imaging neutral 
nanoparticles for in vivo imaging applications. We discuss the development of such systems 
and show how paramagnetic liposomes and imaging nanoparticles could be developed as 
platforms for future multi-functional, multi-modal imaging theranostic nanodevices tailor-
made for the combined imaging of early stage disease pathology and functional drug 
delivery.  
Keywords:  cellular labeling; liposomes; Gadolinium; paramagnetic liposomes; bimodal 
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1. Introduction  
Cellular imaging has been defined as “the visualization of specific cells in an intact animal” but this 
is also a collective term for the visualisation of any type of whole cell under a variety of circumstances 
[1]. Hence cellular imaging concerns the imaging of entire cells whereas molecular imaging seeks to 
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visualise molecules and sub-cellular components within individual cells [2]. Both cellular and 
molecular imaging requires the use of molecular probes (or imaging agents) to facilitate the use and 
applications of either technique. In the case of molecular imaging, the fluorescence imaging of 
extrinsic fluorophores is a very useful method, however, the technique is often depth restricted. 
Additionally, positron emission tomography (PET) or single-photon computed tomography (SPECT) 
have limitations due to short lived radioisotopes and poor spatial resolution. This is not the case for 
magnetic resonance imaging (MRI) which is capable of producing three-dimensional images of tissues 
containing water with a high degree of spatial resolution. However, the main weakness of MRI is an 
inherent lack of sensitivity which is overcome through the use of contrast agents which enhance signal 
sensitivity and hence image quality. MRI contrast agents consist of molecules or nanoparticles that 
incorporate a paramagnetic metal ion, most commonly gadolinium (Gd
3+) or Iron (Fe
3+/Fe
2+). The 
improvement in image quality that arises with these contrast agents, derives from the modulating 
effects of the coordinated metal ions on longitudinal (T1) or transverse (T2) relaxation times associated 
with proton resonance signals emanating from bulk water molecules surrounding the coordinated metal 
ions (see below). Contrast agents incorporating Gd
3+ increase both 1/T1 and 1/T2 relaxivities but are 
generally used in T1-weighted (positive-bright) contrast imaging given that the 1/T1 contribution is 
greater in tissue than the corresponding effect on 1/T2 enhancement. On the other hand, Iron containing 
contrast agents promote more substantial increases in 1/T2 and are generally used in T2-weighted 
(negative-dark) contrast imaging [3]. In the next section we shall look at contrast agents in more detail, 
focusing on Gd
3+based systems. 
2. MRI Contrast Agents 
MRI contrast agents are routinely used in clinical diagnosis as they provide reliable means to 
interpret MR images and can also play a key role in clinical imaging [3]. In general, MR contrast 
agents consist of Gd
3+  complexes, Mn
2+  chloride complexes, or monocrystalline iron oxide 
nanoparticles. In complexes, a paramagnetic metal ion core is associated with a strong chelating 
ligand. Nowadays, the most frequently used contrast agents are thermodynamically and kinetically 
stable low molecular weight Gd
3+ complexes that promote MRI contrast by non-specific enhancement 
of water proton relaxation rates within the blood pool. Gd.DTPA
 (Figure 1) was the first water soluble, 
renally excreteable contrast agent approved for clinical use, and is currently used routinely under the 
commercial name Magnevist
® [4]. Other Gd
3+ contrast agents used commonly in the clinic are also 
shown (Figure 1).  
Figure 1. Commonly used Gadolinium based clinical contrast agents approved by the FDA. 
 
Dotarem
® (Gd.DOTA)
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These contrast agents are stable complexes with Gd
3+ ion strongly chelated to 
poly(aminocarboxylate) ligands. They mostly act non-specifically, mainly reside within the blood 
stream and also accumulate in the kidneys due to glomerular filtration from where they are excreted 
unmetabolised [5]. Their use in clinical MRI has been substantial given that anatomical abnormalities, 
such as gliomas and lesions within the brain, can be visualised with ease. This is due to the fact that 
the blood brain barrier in these instances is porous to such contrast agents, but not under normal 
physiological conditions. Pathologies within the liver and other organs can also be visualised too under 
circumstances where contrast agents are able to accumulate rapidly into regions of increased fluid 
volume in interstitial spaces thereby leading to increases in local MRI signal to noise ratios and image 
quality [6].  
The Gd
3+ ion is of particular utility in MRI owing to its high magnetic moment (7 unpaired 
electrons in its outer shell, 7.9 μB) and slow electron spin relaxation times equivalent to spin relaxation 
times of structural water protons. The principle mechanism for Gd
3+ ion-mediated modulation of 
longitudinal (T1) or transverse (T2) relaxation times is due to t the interaction of an inner sphere water 
molecule with the fluctuating local magnetic field of the paramagnetic Gd
3+ ion. The inner sphere 
water molecule coordinates to the 9
th coordination site of the Gd
3+ ion, leading to the subsequent 
magnetic relaxation of this water molecule. This relaxation has a catalytic effect that leads to the 
relaxation of surrounding bulk water molecules in the vicinity of this co-ordinated water molecule as 
well as via a chemical exchange process. The relaxation process can also be envisaged in terms of a 
Gd
3+ ion mediated polarisation of the O-H bond of the inner sphere coordinated water molecule that 
enhances the magnetic moment of this molecule, and hence dynamically affects surrounding bulk 
water molecules that are in hydrogen bond relationships with the inner sphere water molecule.  
In MRI a static magnetic field is applied which polarizes protons in a sample, producing a net 
magnetisation vector. An RF pulse is then generated which perturbs the net magnetisation vector and 
changes its direction. The magnetisation vector then precesses at a frequency proportional to the static 
applied field, producing the NMR signal which is picked up by an RF receiver. By applying gradients 
to the static magnetic field throughout the sample, the position of each proton atom can be pinpointed 
through slice selection, phase and frequency encoding to produce an MR image (effectively a proton 
density map).  
After the RF pulse is switched off, the magnetisation vector returns to its original direction dictated 
by thermal equilibrium. As it does so, the signal decays (Free Induction Decay, FID). By introducing 
additional random magnetic perturbations Gd
3+ increases the rate of this thermalization and therefore 
decreases the FID rate. Signal processing can be used to extract decay rates and construct proton 
density maps weighted by T1 or T2. These will effectively translate as concentrations of contrast agents 
on an MR image.  
One way to increase the utility of imaging contrast agents is to ensure the loading of as many Gd 
moieties in close proximity as possible. This approach has led to the design and synthesis of 
macromolecular Gd
3+ containing contrast agents that involve the conjugation of many Gd.DOTA or 
Gd.DTPA moieties together on linear, branched or dendrimeric macromolecular polymeric structures 
with powerful capacities to modulate T1 relaxation [7]. However, their routine use in the clinic may be 
hampered by slow clearance and inherent toxicity in vivo, [8,9] although efforts to make these agents 
biodegradable and hence less toxic have been undertaken [10,11]. Nevertheless, applications in MR Int. J. Mol. Sci. 2010, 11                 
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angiography are impressive [12]. Moreover, these macromolecular systems can be bi-functional, that is 
they act simultaneously as imaging contrast agents and drug delivery systems [13]. 
3. Cellular Labelling and MRI 
For cell populations to be imaged by MRI, these populations must be distinguishable from natural 
background noise signal. The ideal cellular label as addressed by Frangioni et al. should posses the 
following characteristics: have a strong signalling effect, good biocompatibility, not interfere with 
cellular genetics, remain retained only in the targeted cell population, and finally, enable temporal 
imaging over long time periods [14]. Clearly cells of interest could be labelled with these agents in 
vitro or ex-vivo and then subsequently re-implanted into specific sites in vivo. Alternatively, cells of 
interest could be labelled with appropriate agents in vivo. Mechanisms of cell entry are shown 
(Figure 2) [15].  
Figure 2. Cell entry mechanisms: the various uptake mechanisms of macromolecules and 
nanoparticles into cells are indicated according to size. 
 
 
There are a number of pathways by which macromolecules and nanoparticles could enter 
mammalian cells, namely by phagocytosis, pinocytosis, clathrin-mediated endocytosis, caveolin-
mediated endocytosis, or clathrin and caveolin independent endocytosis [1,16]. Phagocytosis is a 
process that mediates the uptake of large particles (1 m) by cells and most phagocytic cells of the 
immune system use phagocytosis to internalise foreign bodies. These cells include neutrophils, 
monocytes, macrophages, and microglia. Non-phagocytic cells prefer to internalise particles using 
pinocytosis and it is generally considered that any non-specific internalisation into cells is due to this 
mechanism [1]. Clathrin-mediated endocytosis and caveolin-mediated endocytosis are much the more 
specific means of cellular entry. Int. J. Mol. Sci. 2010, 11                 
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Composed of lipids, similar to cellular bilayers, liposomes or lipid-based nanoparticles represent a 
very useful alternative to macromolecular polymeric structures as carriers of contrast agents, not only 
because they can be adapted to meet the specific requirements of cell labelling vectors, but also to 
meet the general criteria for the development of novel potential MRI contrast agents that can be 
summarized as: an increased thermodynamic stability, favourable rate of excretion, lowered toxicity, 
lipophilicity, target specific biodistribution and an increase in relaxivity. Hence the present review 
will focus on the development of paramagnetic liposomes and imaging nanoparticles with a utility for 
cellular imaging and cancer imaging in vitro and in vivo. For completeness sake, we would like to refer 
the reader to more extensive reviews that concern the syntheses,
 ligand designs and properties of Gd 
contrast agents, in particular clinically relevant agents [17,18].
 
4. Liposome Carriers for Imaging Agents 
Liposomes are composed of lipid constituents, with hydrophobic head groups and hydrophilic tail 
groups (Figure 3). Liposomes are prepared by addition of known molarities of desired lipids together 
in organic solution, the organic solution is then slowly evaporated in vacuo to produce a thin film 
which is then hydrated with a desired aqueous buffer and sonicated. The sonication technique lifts the 
film and creates budding vesicles of bilayers enclosing an aqueous cavity, which achieve a stable size 
once the bilayer has reached a stable equilibrium. The particles are generally on the nanometer scale 
and can be further size refined by passage through physical membrane pores of known size (extrusion). 
Extrusion may also be solely used as a method of preparing liposomes, in particular when drug loading 
capabilities are also required within the liposome aqueous cores.  
Liposomes are typically characterised by their size, shape and lamellarity. They may be composed 
of a single bilayer (unilamellar), a few bilayers (oligolamellar), or multiple bilayers (multilamellar). 
The rigidity of the membrane can also be modified with the use of suitable lipids; and the fluidity of 
the membrane may be controlled using phospholipids with higher or lower LI − HII phase transition 
temperatures. In general lipid derivatives of steric acids (fully saturated C18 lipidic chains) bestow 
rigidity and impermeability to the membrane, whilst lipid derivatives of oleic acid (
9 unsaturated C18 
lipidic chains) result in a more permeable and less stable lipid bilayer. Due to their aqueous cavity and 
“tunable” bilayer, liposomes have traditionally been used as drug delivery vehicles, encapsulating 
water-soluble drugs within the aqueous cavity in order to improve drug pharmacokinetics [19-21]. 
Once liposomes are formulated they can be characterized for their size and surface charge. Liposomes 
can be investigated for their hydrodynamic diameter which is measured using scattered light off the 
surface of the particles with photon correlation spectroscopy, or using cryo-TEM where a visual image 
of the shape and size of the liposomes can be obtained. The surface charge of the liposomes can be 
obtained by measuring their zeta potential (electrokinetic potential).  Int. J. Mol. Sci. 2010, 11                 
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Figure 3. Schematic of liposome self-assembly from lipids. 
 
 
One particularly important modification of liposomes has been the inclusion of synthetic cationic 
lipids into bilayers such that cationic liposomes are formed. These cationic liposomes readily combine 
with nucleic acids to form cationic liposome/nucleic acid (lipoplex) nanoparticles that mediate 
functional delivery of nucleic acids to cells [22-28]. Otherwise, liposomes per se are remarkably 
biocompatible and have been studied as models of biological membranes [29].
 Of particular relevance 
here, liposomes are rendered MRI active (paramagnetic liposomes) by the incorporation of Gd lipids 
into the bilayer structures or by the encapsulation of paramagnetic contrast agents within the aqueous 
cavity [30-32]. These paramagnetic liposomes have been used in a number of investigations including 
cellular labelling and tracking [33]. Indeed, liposomes appear well suited as carriers of a high payload 
of Gd
3+ chelates into cells.  
4.1. Paramagnetic Liposomes by Contrast Agent Encapsulation  
The initial use of paramagnetic MRI-active liposomes came through encapsulation of a   
Gd
3+-containing contrast agent in the aqueous core of liposomes (where water-soluble agents were 
entrapped) or in the bilayer structure (where the lipid soluble agents were concerned) [34-38]. The 
most common form of paramagnetic liposome systems involves the cavity encapsulation of   
FDA-approved clinical contrast agent Magnevist (Gd.DTPA) that has excellent solubility and MR 
signal enhancement properties. Many paramagnetic contrast agents have been prepared in 
paramagnetic liposomes for a range of applications [39,40], assisted by the work of Unger et al. and 
others who have noted that acceptable encapsulation efficiencies of >35% are obtained using a freeze-
thaw extrusion process [41]. In general relaxivity rates associated with Gd
3+ ion-mediated   
T1-relaxation are a function of the exchange rate (tM) of the inner and outer sphere water molecules 
[42]. In addition, the coordination number and the rotational correlation time (tr) are also factors that 
affect relaxivity rates [43]. In the case of paramagnetic liposomes, these effects need to be considered 
alongside other factors such as liposome rigidity that leads to limited water flux between the liposome 
aqueous cavity and outer bulk water, and can impair the overall impact of the contrast agents on local 
tissue water relaxivity [44]. Accordingly, lipid properties such as lipid chain length, the presence of a 
phospholipid head group and degree of saturation [45,46], can be manipulated to engineer 
paramagnetic liposome associated relaxivity rates. One of the best ways to overcome paramagnetic 
liposome rigidity can be to prepare very small liposomes (<50 nm), such that a high surface to volume 
ratio facilitates water exchange. Alternatively, bilayers can be designed to be as permeable as possible 
to water, but this raises issues of instability in biological media such as serum [40].  Int. J. Mol. Sci. 2010, 11                 
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4.2. Paramagnetic Liposomes Involving Gd Lipid Incorporation 
Various parameters exist that can influence the relaxation rate of water molecules within the 
contrast agent’s vicinity. These parameters can be thought of as; the average time (nanoseconds) a 
water molecule remains co-ordinated to the metal ion in the first inner sphere (tM), how fast the 
contrast agent tumbles in water, which is measured by the rotational correlation time (tR) and the 
translational diffusion time of the outer sphere water molecules (tD). This latter parameter is related to 
the hydrogen bonding of the carboxylate oxygens with surrounding water molecules that hydrate the 
complex (oxygen atoms are relaxed via dipolar mechanisms). The relaxivity of paramagnetic 
liposomes has been shown to be mainly effected by the exchange rate (tM) of the coordinated water 
molecule to the Gd metal centre of the membrane anchored paramagnetic lipid. In addition to the 
exchange rate, the coordination number and the rotational correlation time (tr) are also factors that 
affect the relaxivity of macromolecular contrast agents [43]. Possible motions of the enhanced dipole 
moment of the inner sphere water molecule (associated with the Gd chelate head group) are shown that 
are considered to contribute towards relaxation of surrounding water protons in Figure 4 [42]. 
Paramagnetic liposome rigidity (achieved through the use of fully saturated lipids) leads to limited 
water flux between the inner liposome compartment and outer bulk water, therefore affecting the 
overall particle relaxivity [44]. Paramagnetic lipid properties such as lipid chain length and degree of 
saturation [45], in addition to the presence of a phospholipid head group have also been shown to 
affect relaxivity [46]. Given relaxivity problems resulting from the encapsulation of Gd
3+ contrast 
agents inside liposomes, surface attachment of Gd chelates (such as Gd.DTPA or Gd.DOTA) to 
liposome bilayers now appears increasingly preferable. Surface attachment can be expected to enhance 
water contact of the Gd chelate leading to potentially significant relaxivity enhancement effects.  
Figure 4. Cartoon of the possible motions that may occur involving the water molecule 
bound to the Gd
3+ ion of the Gd lipid chelate head group. a shows the rotational motion of 
the whole paramagnetic liposome in water (tr), b shows the translational diffusion of 
individual Gd chelates protruding from the paramagnetic liposome surface (tD(transl)), c 
presents the rotation of the Gd chelated head group attached to the lipid tail (tint) and d 
depicts the rotational diffusion of the entire Gd lipid in the paramagnetic liposome 
membrane (tD(rot)) [42]. 
tr tD(transl) tint tD(rot)
O
H H
Gd
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4.3. Effects of Cellular Compartmentalization of Gd Liposomes on MR Relaxivity 
Once paramagnetic liposomes have passed the first hurdle of cellular entry through envagination of 
the cellular bilayer (endocytosis) and reside in early endosome compartments, the T1 relaxation 
properties of the Gd chelates bound to the lipids becomes limited to the amount of water flux between 
the endosmal and eventually, lysosomal compartments. Terreno et al. have elegantly demonstrated the 
effects of Gd chelate localization and concentration on relaxation properties, with quenching effects 
observed when chelates are trapped in the endosome and at high concentrations of Gd
3+ [47]. 
When considering the cellular labelling efficiencies of single molecule based contrast agents or 
liposomes, factors such as the path of entry into the cell, the intracellular localization and 
concentration of MRI contrast agents must also be taken into account. Lack of sufficient water protons 
to allow for detectable T1 relaxation effects and Gd
3+ concentrations leading to quenching of the T1 
signal are parameters which must also be investigated in future assessments of the efficacies of cell 
labelling contrast agents. Recently a three compartment model representing the extracellular, 
cytoplasmic and vesicular components of cells has offered a theoretical model for the explanation of 
these effects once contrast agents are added to cells [48]. Additionally, Kok et al. have also 
demonstrated that intracellular effects described above directly affect T1 relaxation properties [49]. In 
this study RGD targeted liposomes were used to image αvβ3 overexpression on HUVEC cells, in 
addition to control non-targeted liposomes, and it was shown that despite the additional RGD targeting 
moiety which should increase liposome uptake into the cells, no changes in T1 enhancement were 
observed compared to when the cells were incubated with control non-targeted liposomes. These 
findings, which were explained based on the model by Strijkers et al. were attributed to; the 
concentration of Gd
3+ in the intracellular vesicles post internalization and the physical size of these 
vesicles [49]. With high contrast agents inside the vesicles limiting water flux between the vesicles and 
the cytoplasmic compartment, and due to enhanced uptake for the targeted liposomes, an increase in 
the size of these vesicles leading to an increase in their surface-to-volume ratios, thereby lowering the 
water exchange of the overall membrane [49].  
Kabalka  et al. were the first to demonstrate how to incorporate Gd lipids into paramagnetic 
liposome formulations over 20 years ago and the Gd lipid (Gd.DTPA.BSA) used in their studies is still 
frequently used to prepare paramagnetic liposomes today [50]. Kabalka et al. also clearly 
demonstrated how the attachment of two hydrophobic chains to the DTPA chelate had little effect on 
the ability of DTPA to complex Gd
3+ [51]. On the other hand, they also showed that such liposomes 
containing amphipathic paramagnetic agents (i.e., Gd lipids) were indeed able to enhance significantly, 
the MR signal intensity in T1-weighted MRI. In addition, they were able to observe that their 
paramagnetic liposomes agents were suitable for the imaging of liver, spleen, bone marrow, and other 
organs that are rich in macrophage activity.  
Since that time, a range of Gd lipids have been incorporated into liposome formulations to achieve 
paramagnetic liposomes. The principal design feature of these lipids has been the conjugation of the 
FDA approved Gd.DTPA MRI contrast agent moiety with lipid moieties associated in order to anchor 
the Gd chelate into liposome bilayers. Some examples of paramagnetic Gd lipids synthesised by 
various research groups are presented (Figure 5).  Int. J. Mol. Sci. 2010, 11                 
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Figure 5. Examples of paramagnetic Gd lipids with various hydrophobic tails. 
   
 
Gd.DTPA.BSA [52,53]    PPL: polymerisable paramagnetic lipids [54] 
 
   
 
A paramagnetic dipalmitoylphospho lipid [55]     Gd.DTPA(DSPE)2 derivative [56] 
 
            
 
Gd.DTPA.Cholesterol [57]        Gd.DTPA with aromatic side chain groups [58] 
 
 
 
Gd.DOTA lipid derivatives [59]  
 
Leclercq et al. have reported the design and synthesis of an alternative paramagnetic Gd lipid with 
an additional functionality which further demonstrates additional advantages of liposome systems [60]. 
This novel bi-functional Gd lipid MCO-I-68 (see Figure 6) comprises a cationic head group for DNA 
binding and condensation. Consequently, cationic liposome-mediated transfection of NIH 3T3 cells 
was observed in vitro using cationic liposomes formulated from MCO-I-68 and transfection of mouse 
tumours in vivo was also observed following intratumoural injection. In this instance, transfection 
efficiency was determined throughout using concomitant MRI measurements. This is an excellent 
early example of a bi-functional paramagnetic cationic liposome system. Int. J. Mol. Sci. 2010, 11                 
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Figure 6. bi-functional Gd lipid MCO-I-68 [60]. 
 
5. In Vitro Evaluation of Paramagnetic Liposomes 
To date, cellular labelling with MRI contrast agents has frequently involved the use of iron oxide 
particles. However, Gd
3+ based contrast agents are increasingly used as well. Contrast agent-mediated 
cellular imaging is now a growing field for the tracking of cells of interest and even the monitoring of 
functional cell status as a function of time. As intimated in Section 3 of this review, paramagnetic 
liposomes represent an excellent means of carriage for the functional delivery of associated MRI 
contrast agents to cells for labelling purposes. Recently, Oliver et al. reported on a bi-functional,  
bi-modal imaging paramagnetic cationic liposome system (MAGfect
TM) capable of simultaneous 
labelling of cells of interest (with fluorescent probe and MRI contrast agent) and functional delivery of 
DNA to the same cells [33]. This system was further developed by Kamaly et al. using a novel 
paramagnetic lipid termed Gd.DOTA.DSA (Figure 7) in order to derive a new bi-modal imaging 
paramagnetic liposome system primarily for in vitro use [61].  
The cationic character of this particular bi-modal imaging paramagnetic cationic liposome system 
was conferred by the inclusion of a cationic lipid (CDAN) (Figure 7) that promotes cell surface 
association, cell entry by endocytosis and endosomolysis to enable liposome bilayer-associated 
imaging agents access to the cell cytoplasm (see Figure 8). Endosomolysis is further assisted by the 
lipid fusogenic character of the neutral lipid (DOPE) (Figure 7) that acts as a helper lipid in such 
membrane trafficking events [62-64].
 The inclusion of the cationic lipid was also intended to ensure 
that this particular bi-modal imaging paramagnetic cationic liposome system should also be   
bi-functional with the capacity for plasmid DNA binding, condensation and functional delivery to cells 
in vitro, in the same way as MAGfect
TM [33,61]. Very recently, Kamaly et al. described a next 
generation bi-modal imaging paramagnetic cationic liposome system prepared using the bi-modal 
imaging lipid (Gd.DOTA.Rhoda.DSA) (Figure 7) [65]. This bi-modal imaging lipid was found to be 
even more efficient than the parent Gd-lipid at enhancing water proton relaxivities and lowering T1 
relaxation times.  
We have described several paramagnetic cationic liposomes in this Section that are versatile yet 
robust platforms for the bi-modal labelling of cells of interest (with fluorescent probe and MRI 
contrast agent) in vitro. These same cationic liposomes may also be capable of simultaneous functional 
delivery of nucleic acids to the same cells too. Accordingly, such systems represent the beginning of 
new and increasing moves towards the creation of multi-functional, multi-modal imaging Int. J. Mol. Sci. 2010, 11                 
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paramagnetic liposome systems capable of promoting simultaneous multi-modal imaging of cells in 
vitro and multi-functional adaptations of the same cells. Arguably such multi-functionality/multi-
modality should bring to the fore the true technical capacity and value of paramagnetic liposome 
systems for the cellular imaging of tomorrow. 
Figure 7. Lipidic agents used to formulate paramagnetic liposome nanoparticles [61]. 
 Int. J. Mol. Sci. 2010, 11                 
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Figure 8. Cellular labelling with bimodal liposomes by MRI (top right image) and 
fluorescence microscopy (bottom right image).  
 
6. Paramagnetic Liposomes for in Vivo Applications 
For successful in vivo applications, experience suggests that an outer liposome bilayer should be 
coated with a neutral polymer polyethylene glycol; PEG, in order to minimize the colloidal instability 
of liposomes, to reduce bioadhesion and minimize immunological responses [66,67]. 
PEG incorporation has also been shown to increase relaxivities of MRI contrast agents through the 
provision of additional macromolecular bulk structure, leading to reduced tumbling rates and hence 
increased Gd-metal water contact. In addition, the biocompatibility conferred by a PEG coating has 
proved valuable in MR imaging of tumours in vivo [68], by reducing reticuloendothelial system (RES) 
mediated uptake and disposal of liposome systems [33], Consequently, PEGylated liposomes may in 
fact be considered multi-functional nanoparticle systems that can be “engineered” for different 
applications  in vivo by variations in lipid composition, liposome size, surface charge, type of 
constituent lipids, route of injection and injection volume.  
Accordingly, PEGylated liposomes that also comprise MRI contrast agents can be expected to be 
potent imaging nanoparticle systems for in vivo MRI applications. This has been demonstrated 
convincingly in a number of studies. Ayyagari et al. have recently reported the encapsulation of 
contrast agents in PEGylated liposomes [69]. Erdogan et al., and others, have recounted the 
development of antibody-targeted PEGylated liposomes wherein a polymeric Gd chelate is anchored to 
liposome bilayers by an attached lipid moiety [70].  
Recently Mulder et al. have imaged angiogenesis by detecting the over-expression of αvβ3 integrins 
in tumour bearing mice using a combination of MRI and fluorescence microscopy [71]. They prepared 
paramagnetic and fluorescent liposomes, surface modified with the cyclic RGD amino acid sequence. 
These RGD functionalised liposomes were shown to target the vessel walls of cancer cells both in 
vitro and in vivo. Fluorescence microscopy revealed that both the control non-paramagnetic and 
paramagnetic RGD liposomes targeted the vessel wall. The use of fluorescence microscopy in this 
study differentiated between the activity of the targeted RGD (which strongly bound to the αvβ3 
receptor) and the control liposome modified with the control peptide sequence, RAD (Glycine (G) 
replaced by Alanine (A)), which has no affinity for the receptor. Int. J. Mol. Sci. 2010, 11                 
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The versatile nature of liposomes allows for their targeting to various disease markers. Targeting 
moieties in the forms of ligands, peptides, proteins or specific antibodies can be conjugated onto the 
surface of liposomes via the use of standard bioconjugation techniques. Gd based paramagnetic 
liposomes were formulated using the Gd.DTPA.BSA lipid by Brandwijk et al. [72]. The incorporation 
of a maleimide PEG lipid into the liposome formulation allowed for the surface attachment of anginex, 
a 33-mer angiostatic peptide which has been shown to home to activated endothelium undergoing 
angiogenesis. MRI and fluorescence microscopy of these targeted liposomes which also incorporated a 
fluorescent lipidic probe showed specific binding of these agents to activated endothelial HUVECs. A 
similar approach and liposome model was also used by Mulder et al. for the conjugation of an anti-E-
selectin monoclonal antibody as a targeting ligand towards activated endothelial cells [73].  
In our case, Kamaly et al. have described the inclusion of Gd lipid Gd.DOTA.DSA and a 
Rhodamine-labelled lipid (DOPE-Rhodamine) (Figure 7) into two main types of neutral PEGylated 
liposomes to give highly effective bi-modal imaging neutral nanoparticles for in vivo use. The first 
such imaging nanoparticle developed (also known as fluorescent Gd
3+-BC nanoparticles according to 
the ABCD nanoparticle concept) [22] was designed for the simultaneous MRI of tumour lesions in 
vivo , fluorescent imaging ex vivo and nucleic acid delivery in vitro (Gd
3+-ABC) [61]. This system was 
subsequently adapted for targeting to ovarian xenograft tumours by the PEG surface attachment of 
folate ligands [74]. The resulting targeted bi-modal imaging neutral nanoparticles (also known as 
fluorescent Gd
3+-BCD nanoparticles according to the ABCD nanoparticle concept) [22] were shown to 
mediate highly efficient functional delivery of contrast agent and fluorophore to tumour cells within 
the initial imaging time period of just 2h. Variations of these Gd
3+-ABC and ABCD nanoparticles are 
now the subject of preclinical development and it is hoped that these systems can become genuine 
clinical-grade imaging nanoparticles for tumour MRI. Recently, a next generation bi-modal imaging 
neutral nanoparticle (fluorescent Gd
3+-ABC nanoparticle) making use of the bi-modal lipid 
Gd.DOTA.Rhoda.DSA (Figure 7) to improve further nanoparticle-mediated contrast agent and 
fluorescence probe labelling of tumour cells in vivo was also developed and successfully utilized for in 
vivo tumour imaging [65]. 
7. Conclusions 
Here we have set out to summarize recent progress made in the preparation, formulation and 
investigation of the applications of paramagnetic liposome systems through to imaging nanoparticle 
systems. These current systems may have real potential to be clinical MRI contrast agents. However 
this is just the beginning. Once the genuine utility of bi-modal imaging neutral nanoparticles can be 
demonstrated in the clinic, then we are confident that next steps will be to see the emergence of 
varieties of multifunctional, multi-modal imaging nanoparticles (nanodevices) ideal for clinical 
diagnosis of early stage disease pathology, mediation of functional drug delivery (therapy) and even 
theranostics (where diagnosis and therapy can be realized within one major therapeutic nanodevice). 
Moreover, the very diversity of lipid structures in nature and available from chemical synthesis should 
ensure that multi-functional, multi-modal imaging nanoparticles can be truly tailor-made or engineered 
for individual disease requirements and even individual patient requirements making such devices 
perfectly applicable to the personalized medicines of tomorrow. Int. J. Mol. Sci. 2010, 11                 
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